Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
News|Articles|June 5, 2015
New AmpliPhi Facility Receives cGMP Certification
Author(s)Pharmaceutical Technology Editors
AmpliPhi announces that its new facility in Slovenia has received cGMP certification to manufacture bacteriophages for clinical trials.
Advertisement
On June 3, 2015, AmpliPhi BioSciences announced that its production facility in Ljubljana, Slovenia was cleared by the Agency of the Republic of Slovenia for Medicinal Products and Medical Devices to manufacture bacteriophages under cGMP standards. The 600-square-meter facility will be used to produce Staphylococcus aureus and Pseudomonas aeruginosa for planned human clinical trials. AmpliPhi focuses on developing bacteriophage-based antibacterial therapies to treat drug resistant infections, according to a press release. Completion of the facility allows AmpliPhi to exhibit control of the manufacturing process for bacteria and phages to be used in clinical trials, rather than to rely on outsourcing.
“This clearance is a pivotal regulatory milestone that further supports AmpliPhi’s leadership in the field of bacteriophage with the only cGMP-certified manufacturing facility in the world dedicated to producing bacteriophage products for human use. In addition, this clearance allows us to advance our proprietary clinical program and validates our technology platform for a broad range of bacteriophage therapeutic applications and collaborations,” said M. Scott Salka, CEO of AmpliPhi, in a press release.
Source:
Advertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement